Search results for "Adrenergic"

showing 10 items of 433 documents

Complex regional pain syndrome:intradermal injection of phenylephrine evokes pain and hyperalgesia in a subgroup of patients with upregulated α1-adre…

2018

The aim of this study was to determine whether upregulated cutaneous expression of α1-adrenoceptors (α1-AR) is a source of pain in patients with complex regional pain syndrome (CRPS). Immunohistochemistry was used to identify α1-AR on nerve fibres and other targets in the affected and contralateral skin of 90 patients, and in skin samples from 38 pain-free controls. The distribution of α1-AR was compared between patients and controls, and among subgroups of patients defined by CRPS duration, limb temperature asymmetry, and diagnostic subtype (CRPS I vs CRPS II). In addition, α1-AR expression was investigated in relation to pain and pinprick hyperalgesia evoked by intradermal injection of th…

AdultMale0301 basic medicineAgonistInjections Intradermalmedicine.drug_classPainAdrenergicClonidinePhenylephrineYoung Adult03 medical and health sciences0302 clinical medicineReceptors Adrenergic alpha-1Adrenergic alpha-2 Receptor AgonistsmedicineHumansIntradermal injectionPhenylephrineAgedbusiness.industryMiddle Agedmedicine.diseaseUp-Regulation030104 developmental biologyAnesthesiology and Pain MedicineComplex regional pain syndromeNociceptionNeurologyHyperalgesiaAnesthesiaHyperalgesiaImmunohistochemistryFemaleAdrenergic alpha-1 Receptor AgonistsNeurology (clinical)medicine.symptombusinessComplex Regional Pain SyndromesReceptors Purinergic P2X3030217 neurology & neurosurgerymedicine.drug
researchProduct

β2-adrenoreceptors control human skin microvascular reactivity.

2021

Topical α1- and α2-adrenoreceptor (ADRA1 and 2) agonists are effective in alleviating permanent vasodilation and facial erythema associated with rosacea by inducing skin vasoconstriction. Although β-adrenoreceptor (ADRB) antagonists are used off-label for rosacea, pharmacological and pharmacodynamic data pertaining to these receptors in skin micro-vessels are lacking. Objectives: To analyse the expression of different adrenergic receptors and their contribution to vasoreactivity in skin micro-vessels. Small arteries (500-800 μm) and arterioles (<200 μm) were studied in human foreskin tissue. Specifically, ADR-A1, -A2, -B1 and -B2 expression was assayed by immunofluorescence, polymerase chai…

AdultMaleAdrenergic receptorAdolescentForeskinVasodilationHuman skinDermatologyPharmacologyYoung AdultReceptors Adrenergic alpha-2medicinePrazosinHumansRNA Messengerintegumentary systembusiness.industryBrimonidineArteriesVasodilationArteriolesmedicine.anatomical_structureReceptors Adrenergic beta-2medicine.symptombusinessPerfusionVasoconstrictionmedicine.drugArteryEuropean journal of dermatology : EJD
researchProduct

Association between reduced lymphocyte beta-adrenergic receptors and left ventricular dysfunction in young obese subjects

1994

This study was designed to evaluate total (t) and surface (s) beta-adrenergic receptors (BAR) density and their relationships with left ventricular function in young obese subjects. BAR density, plasma insulin, catecholamines and left ventricular function were evaluated in 27 young obese subjects (BMI30.5 kg/m2 for males and27.3 kg/m2 for females) without other risk factors for cardiovascular diseases (smoking, hypertension, diabetes and lipid abnormalities) and in 20 lean controls (BMI25 kg/m2 for males and24.7 kg/m2 for females). Both groups were matched for gender, age and body height. BAR density was evaluated according to Böyum and De Blasi methods. Plasma catecholamines by high perfus…

AdultMaleAgingSettore MED/09 - Medicina InternaRadioimmunoassayPeripheral obesity Central Obesity lymphocyte beta adrenergic receptors left ventricular functionStroke VolumeSettore MED/11 - Malattie Dell'Apparato CardiovascolareVentricular Function LeftCatecholaminesEchocardiographyReceptors Adrenergic betaHumansInsulinRegression AnalysisFemaleLymphocytesObesityCardiac OutputRadionuclide AngiographyChromatography High Pressure Liquid
researchProduct

The use of esmolol in whole-body hyperthermia: Cardiovascular effects

1997

Whole-body hyperthermia (WBH) is a well-described investigational adjunct to systemic chemotherapy for the treatment of advanced malignancies. The hemodynamic consequences of this physiologic state may include tachycardia, which can produce acute myocardial ischemia in patients with coronary artery disease. Ischemic heart disease is currently considered a contraindication to WBH. We chose to investigate the consequences of using a new beta 1-adrenergic antagonist, esmolol, to attempt to control the tachycardia associated with WBH. After institutional approval and patient consent, nine consecutive patients with normal cardiac function presenting for WBH with carboplatin infusion were studied…

AdultMaleCancer ResearchMean arterial pressureCardiac outputHeart diseasePhysiologySinus tachycardiaAdrenergic beta-AntagonistsCardiac indexAntineoplastic AgentsCoronary DiseaseCarboplatinPropanolaminesHeart RateNeoplasmsTachycardiaPhysiology (medical)Heart rateHumansMedicineInfusions Intravenousbusiness.industryContraindicationsHemodynamicsHyperthermia InducedMiddle Agedmedicine.diseaseEsmololCombined Modality TherapyAnesthesiaHeart failureFemaleSafetymedicine.symptombusinessmedicine.drugInternational Journal of Hyperthermia
researchProduct

The novel combination of theophylline and bambuterol as a potential treatment of hypoxemia in humans.

2017

Hypoxemia can be life-threatening, both acutely and chronically. Because hypoxemia causes vascular dysregulation that further restricts oxygen availability to tissue, it can be pharmacologically addressed. We hypothesized that theophylline can be safely combined with the β2-adrenergic vasodilator bambuterol to improve oxygen availability in hypoxemic patients. Ergogenicity and hemodynamic effects of bambuterol and theophylline were measured in rats under hypobaric and normobaric hypoxia (12% O2). Feasibility in humans was assessed using randomized, double-blind testing of the influence of combined slow-release theophylline (300 mg) and bambuterol (20 mg) on adverse events (AEs), plasma K+,…

AdultMaleCombination therapyPhysiologyAdrenergicBiological Availability030204 cardiovascular system & hematologyPharmacologyHypoxemia03 medical and health sciencesYoung Adult0302 clinical medicineTheophyllinePhysiology (medical)Physical Conditioning AnimalmedicineTerbutalineAnimalsHumansTheophyllineDrug InteractionsBambuterolHypoxiaPharmacologybusiness.industryHemodynamicsGeneral MedicineDrug interactionHypoxia (medical)RatsBlood pressureTreatment OutcomeAnesthesiaFemalemedicine.symptomSafetybusiness030217 neurology & neurosurgerymedicine.drugHalf-LifeCanadian journal of physiology and pharmacology
researchProduct

Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans

2004

BACKGROUND: St John's wort (Hypericum perforatum) is a popular over-the-counter antidepressant. Its antidepressive effect has been attributed in part to inhibition of monoamine transporters and monoamine oxidase, on the basis of in vitro studies. METHODS: In a double-blind, randomized, placebo-controlled, crossover study, 16 healthy subjects (11 men and 5 women; mean age, 31 +/- 5 years) ingested either St John's wort (300 mg three times daily) or placebo for 7 days. Imipramine treatment (50 mg three times daily) in 7 subjects served as a positive control. After treatment, physiologic and biochemical tests included cardiovascular reflex testing, graded head-up tilt testing, and plasma catec…

AdultMaleNitroprussideImipraminemedicine.medical_specialtyPosturePharmacologyAutonomic Nervous SystemPlaceboMethoxyhydroxyphenylglycolNorepinephrine uptakeCardiovascular Physiological PhenomenaNorepinephrineCatecholaminesDouble-Blind MethodInternal medicineHeart rateSupine PositionmedicineHumansNitric Oxide DonorsPharmacology (medical)PeryleneAnthracenesPharmacologyCross-Over StudiesAdrenergic Uptake Inhibitorsbusiness.industryHemodynamicsHypericum perforatumEndocrinologyBlood pressureMonoamine neurotransmitterCatecholamine34-Dihydroxyphenylacetic AcidAntidepressantFemalebusinessHypericummedicine.drugClinical Pharmacology &amp; Therapeutics
researchProduct

Plectin-related scapuloperoneal myopathy with treatment-responsive myasthenic syndrome

2020

AdultMalePathologymedicine.medical_specialtyHistologymyasthenic syndromeMuskel- und KnochenstoffwechselPathology and Forensic MedicineEpidermolysis bullosa simplexAdrenergic AgentsPhysiology (medical)medicineHumansMuscular dystrophyFrameshift MutationEphedrineMyasthenic Syndromes Congenitalbusiness.industryPlectin-relatedPlectinmedicine.diseaseScapuloperoneal myopathyMuscular Dystrophy Emery-Dreifusstreatment-responsiveNeurologyPlectinNeurology (clinical)business
researchProduct

Reslizumab as add-on therapy in patients with refractory asthma

2020

### Key messages #### What is the key question? #### What is the bottom line? #### Why read on? Asthma is a common disease, affecting an estimated 334 million people worldwide, with considerable impact on quality of life and high associated costs.1–3 Asthma severity is assessed retrospectively from the level of treatment required to control symptoms and exacerbations. Approximately 5%–10% of patients with asthma are believed to suffer from severe disease.4 Patients with severe asthma typically require ongoing maintenance therapy with high-dose inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA).2 Furthermore, systemic corticosteroids (SCS) are often required for potentially life-th…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classCost-Benefit Analysislcsh:MedicineInflammationAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciences0302 clinical medicineReslizumabQuality of lifeMaintenance therapyAdrenal Cortex HormonesInternal medicinemedicineHumans1506Anti-Asthmatic Agents030212 general & internal medicineChildAdrenergic beta-2 Receptor AgonistsPulmonary EosinophiliaAgedAsthmalcsh:RC705-779business.industrylcsh:Rlcsh:Diseases of the respiratory systemMiddle AgedEosinophilmedicine.diseaseAsthmarespiratory tract diseasesTreatment Outcomemedicine.anatomical_structure030228 respiratory systempulmonary eosinophiliaRegression AnalysisCorticosteroidFemalemedicine.symptombusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

Vasopressin receptors involved in adrenergic neurotransmission in the circular muscle of the human vas deferens

1998

We studied the effects of vasopressin on the adrenergic responses of in vitro preparations of circular muscle from the vas deferens obtained from 28 men undergoing elective vasectomy. Vasopressin (3 x 10(-9)-3 x 10(-8) M) enhanced the phasic contractions elicited by electrical field stimulation and noradrenaline. This potentiation was blocked by the vasopressin V1 receptor antagonist d(CH2)5Tyr(Me)vasopressin (10(-6) M) but not by the vasopressin V2 receptor antagonist [d(CH2)5, D-Ile2,Ile4,Arg8]vasopressin (10(-6) M). The Ca2+ antagonist nifedipine (10(-6) M) did not affect the potentiation of electrical field stimulation induced by vasopressin and noradrenaline but reduced KCl-induced con…

AdultMaleReceptors Vasopressinmedicine.medical_specialtyVasopressinNifedipineVasopressinsNeuropeptideAdrenergicStimulationIn Vitro TechniquesSynaptic TransmissionPotassium ChlorideNorepinephrineHormone AntagonistsVas DeferensInternal medicinemedicineHumansVasoconstrictor AgentsVasopressin receptorPharmacologyArginine vasopressin receptor 1BChemistryAntagonistVas deferensMuscle SmoothCalcium Channel BlockersElectric StimulationArginine Vasopressinmedicine.anatomical_structureEndocrinologyAdrenergic alpha-AgonistsAntidiuretic Hormone Receptor Antagonistshormones hormone substitutes and hormone antagonistsMuscle ContractionEuropean Journal of Pharmacology
researchProduct

Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine

2002

It has been proposed that norepinephrine plays a critical role in the modulation of cortical excitability, which in turn is thought to influence functional recovery from brain lesions. The purpose of the present experiments was to determine if it is possible to modulate cortical excitability with the selective norepinephrine reuptake inhibitor reboxetine in intact humans. Recruitment curve and intracortical facilitation, assessed by transcranial magnetic stimulation, were increased after oral intake of 8 and 4 mg reboxetine, in the absence of changes in motor threshold, intracortical inhibition, M-response, F-wave or H-reflex. These results demonstrate that reboxetine enhances cortical exci…

AdultMaleRecruitment NeurophysiologicalMorpholinesmedicine.medical_treatmentCentral nervous systemNorepinephrine (medication)MagneticsReboxetinemedicineHumansNeurorehabilitationAdrenergic Uptake InhibitorsElectromyographyGeneral NeuroscienceReboxetineMotor CortexNeural InhibitionEvoked Potentials MotorTranscranial magnetic stimulationmedicine.anatomical_structureCatecholamineReuptake inhibitorPsychologyNeuroscienceMotor cortexmedicine.drugNeuroscience Letters
researchProduct